Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in Obesity
Status:
Completed
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
This study is being done to assess the stomach emptying effect of a maximum dose of 3 mg
Liraglutide compared to placebo in subjects who are overweight or obese. Liraglutide is a
medication approved by the Food and Drug Administration (FDA) for routine clinical use.
Phase:
Phase 2
Details
Lead Sponsor:
Michael Camilleri Michael Camilleri, MD
Collaborators:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) Novo Nordisk A/S